Lumobiotics GmbH

Lumobiotics GmbH

Startup developing anti-cancer & anti-microbial photocontrollable peptidomimetics.

Founded 2017 Germany

Karlsruhe, Germany 2-10 employees Grant Total: $168.00K Biotechnology, Health Care +1

Lumobiotics is a German biotechnology startup, founded in 2017, that focuses on developing innovative anti-cancer and anti-microbial photocontrollable peptidomimetics. The company’s mission is to create light-controllable peptide drugs that serve as safe cytolytic agents for the treatment of solid cancers and localized infectious diseases. Lumobiotics achieves this through the use of molecular photoswitches and is dedicated to advancing the development of chemotherapeutics based on this technology platform. The drug candidates developed by Lumobiotics are peptidic therapeutics which have been modified by photoisomerizable building blocks. These drugs have the ability to toggle between inactive and active forms upon exposure to light of different wavelengths. The inactive and non-toxic photoswitchable peptidic drugs are administered to patients, and their biological activity can be switched on in the targeted sites, such as tumors and wounds, through non-thermal red light irradiation. This approach allows for the avoidance of side effects in healthy tissues. Lumobiotics' current target indications include bladder cancers, hepatocellular carcinoma, and implant infections. The company received a €168.00K grant investment on 01 March 2021, indicating both investor interest and potential for the continued development of their groundbreaking technologies. Lumobiotics operates at the intersection of biotechnology and healthcare, addressing critical needs in the treatment of cancer and infectious diseases with its innovative approach to drug development.

Funding Stage	Amount	Investors	Lead Investors	Date
Grant	€168.00K	-		01 Mar 2021

Funding Stage

Amount

Investors

Lead Investors

Date

Grant

€168.00K

01 Mar 2021

FAQ About Lumobiotics GmbH

Startup developing anti-cancer & anti-microbial photocontrollable peptidomimetics.

Lumobiotics GmbH was founded in 2017.

Lumobiotics GmbH is headquartered in Karlsruhe, Germany.

Lumobiotics GmbH operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Pharmaceuticals, Oncology, Infectious diseases and Peptides.

Lumobiotics GmbH has approximately 2-10 employees.

Lumobiotics GmbH has completed 1 funding round, raising a total of $168.00K. The latest funding stage is Grant.

Top alternatives and competitors to Lumobiotics GmbH include TenNor Therapeutics, Concortis Biosystems Corp, Antlia Bioscience, Inc., Moderna, Iyuda Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Lumobiotics GmbH and TenNor Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Lumobiotics GmbH

Funding Rounds & Investors (1)

Lumobiotics GmbH Alternatives & Competitors

FAQ About Lumobiotics GmbH